Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.52 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782653 | 0.89 | F2 (0.53) | MEP1BCYP2C19AKR1C3HTTF2 | |
| SCHEMBL7690859 | 0.88 | MEP1B (0.62) | MEP1BCYP2C19AKR1C3HTTMAPK1 | |
| SCHEMBL7673440 | 0.85 | MEP1B (0.60) | MEP1BKMT2AF2TMPRSS6ALDH1A1 | |
| SCHEMBL7650172 | 0.84 | PRMT1 (0.52) | MEP1BCYP2C19AKR1C3KMT2AF2 | |
| SCHEMBL7402207 | 0.84 | MEP1B (0.65) | MEP1BCYP2C19AKR1C3HTTMAPK1 | |
| SCHEMBL7685704 | 0.80 | CYP2C19 (0.44) | MEP1BCYP2C19AKR1C3HTTTDP1 | |
| SCHEMBL13614830 | 0.79 | CYP2C19 (0.76) | MEP1BCYP2C19AKR1C3HTTMAPK1 | |
| SCHEMBL30866646 | 0.79 | CYP2C19 (0.76) | MEP1BCYP2C19AKR1C3HTTMAPK1 | |
| SCHEMBL27802295 | 0.78 | CA1 (0.54) | MEP1BCYP2C19AKR1C3KMT2AF2 | |
| SCHEMBL2281070 | 0.78 | CYP2C19 (0.70) | MEP1BCYP2C19AKR1C3HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105440032-B | Pyrazines derivatives as ENAC blocking agents | 诺华股份有限公司 | 2017-12-08 | — | — | CN | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| CN-105440032-A | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG | 2016-03-30 | — | — | CN | disclosed |
| CN-103249723-B | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| CN-103249723-A | Pyrazine derivatives as enac blockers | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | MEP1B 519/4885CYP2C19 1366/4885AKR1C3 649/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | MEP1B 519/4885CYP2C19 1366/4885AKR1C3 649/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | MEP1B 519/4885CYP2C19 1366/4885AKR1C3 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.